Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 507-514

  Kamdem, Landry K ^a   Hamilton, Leo ^a   Cheng, Cheng ^a   Liu, Wei ^a   Yang, Wenjian ^a   Johnson, Julie A ^c   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Acute lymphoblastic leukemia; Glucocorticoids; Hypertension; Single nucleotide polymorphism

Indexed keywords

ANTILEUKEMIC AGENT; CREATININE; GLUCOCORTICOID; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; APOLIPOPROTEIN B GENE; ARTICLE; BGLAP GENE; BODY MASS; CHILD; CNTNAP2 GENE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRHR1 GENE; CYTOCHROME P450 3A4 GENE; CYTOCHROME P450 3A5 GENE; DNA POLYMORPHISM; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFANT; LEPR GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NTAN1 GENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SODIUM CHLORIDE COTRANSPORTER GENE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; INFANT; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGRESSION ANALYSIS;

EID: 44449095468     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fc5801     Document Type: Article

References (50)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350:1535-1548.
2. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211-1218.
3. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101:3809- 3817.
4. Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al-Musa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003; 97:2898-2903.
5. Kaste SC, Jones-Wallace D, Rose SR, Boyett JM, Lustig RH, Rivera GK, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15:728-734.
6. Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001; 23:424-430.
7. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22:3930-3936.
8. Trimis G, Moschovi M, Papassotiriou I, Chrousos G, Tzortzatou- Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. J Pediatr Hematol Oncol 2007; 29:309-314.
9. Rivera GK, Evans WE, Kalwinsky DK, Mirro J, Ochs J, Dow LW, et al. Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol 1985; 3:201-206.
10. Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992; 84:252-256.
11. Attard-Montalto SP, Saha V, Ng YY, Kingston JE, Eden OB. High incidence of hypertension in children presenting with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994; 11:519-525.
12. Schuetz EG, Wrighton SA, Barwick JL, Guzelian PS. Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. J Biol Chem 1984; 259: 1999-2006.
13. Schuetz EG, Guzelian PS. Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J Biol Chem 1984; 259:2007-2012.
14. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75:1059-1069.
15. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95:1297-1300.
16. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2:171-182.
17. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
18. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21:3084-3091.
19. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92:411-415.
20. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004; 83 (suppl 1):S124-S126.
21. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690-2696.
22. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752-4758.
23. Cheng C, Pounds SB, Boyett JM, Pei D, Kuo ML, Roussel MF. Statistical significance threshold criteria for analysis of microarray gene expression data. Stat Appl Genet Mol Biol 2004; 3: article 36.
24. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Pacific Grove, California: Wadsworth and Brooks; 1984.
25. Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab 2003; 17:575-589.
26. Pirpiris M, Yeung S, Dewar E, Jennings GL, Whitworth JA. Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertens 1993; 6:287-294.
27. Tam SH, Williamson PM, Kelly JJ, Whitworth JA. Autonomic blockade amplifies cortisol-induced hypertension in man. Clin Exp Pharmacol Physiol 1997; 24:31-33.
28. Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ. The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 2002; 20:1035-1043.
29. Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens 2000; 14:195-198.
30. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989; 7:537-549.
31. Rice T, Rankinen T, Province MA, Chagnon YC, Perusse L, Borecki IB, et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation 2000; 102:1956-1963.
32. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 2003; 82:1-9.
33. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006; 354:1370-1377.
34. Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D, Mantzoros CS. The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J Clin Endocrinol Metab 2001; 86:4434-4439.
35. Rosmond R, Chagnon YC, Holm G, Chagnon M, Perusse L, Lindell K, et al. Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab 2000; 85:3126-3131.
36. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13:1353-1359.
37. Drolet G, Rivest S. Corticotropin-releasing hormone and its receptors; an evaluation at the transcription level in vivo. Peptides 2001; 22:761-767.
38. Funada M, Hara C, Wada K. Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur J Pharmacol 2001; 430:277-281.
39. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12:24-30.
40. Matsuo A, Katsuya T, Ishikawa K, Sugimoto K, Iwashima Y, Yamamoto K, et al. G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. J Hypertens 2004; 22:2123-2127.
41. Nishiyama K, Tanaka Y, Nakajima K, Mokubo A, Atsumi Y, Matsuoka K, et al. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 ( + 78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia 2005; 48:1335-1338.
42. Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 2003; 52:2848-2853.
43. Bydlowski SP, Novak EM, Issa JS, Forti N, Giannini SD, Diament J. DNA polymorphisms of apolipoprotein B and AI-CII-AIV genes in a Brazilian population: a preliminary report. Braz J Med Biol Res 1996; 29:1269-1274.
44. Salazar LA, Cavalli SA, Hirata MH, Diament J, Forti N, Giannini SD, et al. Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia. Braz J Med Biol Res 2000; 33:1301-1304.
45. Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L, et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006; 24:923-929.
46. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension 1991; 17:102-108.
47. Williams GH. Genetic factors associated with volume-sensitive hypertension. Mol Cell Endocrinol 2004; 217:41-44.
48. Fauvel JP, Laville M. Hypertension in blacks. Presse Med 2006; 35:1067-1071.
49. Bernal-Mizrachi C, Xiaozhong L, Yin L, Knutsen RH, Howard MJ, Arends JJ, et al. An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension. Cell Metab 2007; 5:91-102.
50. Wirtz PH, von Kanel R, Emini L, Ruedisueli K, Groessbauer S, Maercker A, et al. Evidence for altered hypothalamus-pituitary-adrenal axis functioning in systemic hypertension: blunted cortisol response to awakening and lower negative feedback sensitivity. Psychoneuroendocrinology 2007; 32:430-436.